| scholarly article | Q13442814 |
| P50 | author | Gustavo H Dayan | Q88585456 |
| Joan Bevilacqua | Q117812082 | ||
| P2093 | author name string | Mike Watson | |
| Rex Biedenbender | |||
| Anne M Gregg | |||
| P2860 | cites work | Epidemiology and transmission dynamics of West Nile virus disease | Q24603195 |
| Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys | Q27469631 | ||
| West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays | Q27469785 | ||
| A live, attenuated recombinant West Nile virus vaccine | Q27473138 | ||
| Pathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion | Q27477543 | ||
| Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine | Q27477782 | ||
| Preparation and immunogenic properties of a recombinant West Nile subunit vaccine | Q27478202 | ||
| Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine | Q27486149 | ||
| A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial | Q27488963 | ||
| Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model | Q27489554 | ||
| Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States | Q27860919 | ||
| The outbreak of West Nile virus infection in the New York City area in 1999 | Q29618175 | ||
| ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy | Q34362322 | ||
| West Nile encephalitis: an emerging disease in the United States | Q34398570 | ||
| West Nile virus vaccine | Q35010565 | ||
| West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention | Q35214323 | ||
| West Nile virus in the Americas | Q37369061 | ||
| Surveillance for human West Nile virus disease - United States, 1999-2008. | Q39886491 | ||
| A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus | Q40492934 | ||
| An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development | Q40495736 | ||
| A recombinant envelope protein vaccine against West Nile virus | Q40507551 | ||
| Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis | Q40518762 | ||
| Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells | Q40520793 | ||
| Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge | Q40534658 | ||
| The epidemic of West Nile virus in the United States, 2002. | Q40538334 | ||
| Equine vaccine for West Nile virus | Q40543853 | ||
| Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti | Q40548538 | ||
| Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus | Q40549292 | ||
| Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes | Q40551476 | ||
| Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination | Q40597122 | ||
| In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. | Q40641221 | ||
| CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS. | Q40965650 | ||
| Immunization of mice against West Nile virus with recombinant envelope protein | Q43035070 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| West Nile virus | Q158856 | ||
| placebo | Q269829 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 75-84 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults | |
| P478 | volume | 203 |
| Q27321020 | A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations |
| Q36607383 | A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice |
| Q38184218 | A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available |
| Q37236968 | A review of vaccine approaches for West Nile virus |
| Q38866173 | An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection |
| Q37123147 | An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody |
| Q91129614 | An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults |
| Q43047253 | Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination |
| Q33909344 | Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine. |
| Q36043444 | Comparison of β-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus |
| Q30148695 | Cost effectiveness of a targeted age-based West Nile virus vaccination program |
| Q38586294 | Current status and future prospects of yellow fever vaccines |
| Q34788758 | Current trends in West Nile virus vaccine development |
| Q30250251 | Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen. |
| Q33584872 | Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery |
| Q66679185 | In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment |
| Q40222732 | Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice |
| Q40275080 | Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. |
| Q28082778 | Plant-made vaccines against West Nile virus are potent, safe, and economically feasible |
| Q37666763 | Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus |
| Q21284433 | Recent progress in West Nile virus diagnosis and vaccination |
| Q91656676 | Role of NS1 and TLR3 in Pathogenesis and Immunity of WNV |
| Q40324111 | Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects |
| Q37254256 | TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate |
| Q38269151 | Technologies for the development of West Nile virus vaccines |
| Q52880885 | The Immune Responses of the Animal Hosts of West Nile Virus: A Comparison of Insects, Birds, and Mammals. |
| Q35492767 | The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys |
| Q26865102 | The yellow fever 17D virus as a platform for new live attenuated vaccines |
| Q93155035 | Twenty Years of Progress Toward West Nile Virus Vaccine Development |
| Q26865618 | West Nile Virus: biology, transmission, and human infection |
| Q38074266 | West Nile virus infection and immunity |
| Q37434776 | West Nile virus state of the art report of MALWEST Project |
| Q51860606 | West nile virus. |
Search more.